Trial Profile
A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Seltorexant (JNJ-42847922) on Electrocardiogram Intervals in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 14 Sep 2018 Status changed from recruiting to completed.
- 03 May 2018 Status changed from not yet recruiting to recruiting.
- 13 Apr 2018 New trial record